Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography

The HANSE study, led by Jens Vogel-Claussen and colleagues, explores the potential of a national lung cancer screening program in Germany using Low-Dose Computed Tomography (LDCT). Aiming to reduce lung cancer mortality, the study targets high-risk individuals, defined using the NELSON and PLCOM2012 risk models. It compares the effectiveness of these models in detecting early-stage lung cancer and investigates the value of adding coronary calcium and emphysema scoring to LDCT reports. Over 5,000 high-risk participants are screened, with 7,100 low-risk individuals serving as controls. The study uses a modified Lung-RADS 1.1 system for lung nodule analysis and monitors patients for up to 10 years. Findings highlight LDCT’s potential not only in cancer detection but also in identifying risks for cardiovascular diseases, which could prompt preventive measures. Aview’s advanced technology aids in managing lung nodule data, contributing to the accuracy and comprehensiveness of the screening process.